title: Randomized study of pre-induction cervical ripening with sequential use of intravaginal prostaglandin E2 gel.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of serial frequent intravaginal prostaglandin (PG) E2 gel applications in shortening the time required to achieve an inducible cervix.
  
  
  METHODS
  From May 1, 1993, through April 30, 1994, 101 pregnant women with medical indications for induction of labor and Bishop scores less than 7 were randomized to receive intravaginal 2.5 mg of PGE2 gel every 6 hours or as often as every hour until the Bishop score was at least 7 or intervention was required.
  
  
  RESULTS
  The mean total number of PGE2 gel applications was significantly different between the 1- and 6-hour groups, 6.5 and 4.4 PGE2 applications, respectively. The mean time from PGE2 application to delivery was similar, 42 and 45 hours, for the 1- and 6-hour groups, respectively. The intervention rate, occurrence of labor during ripening, and neonatal outcomes were also similar.
  
  
  CONCLUSIONS
  Intravaginal application of 2.5 mg PGE2 gel as frequently as every hour appears to be safe, but it does not decrease the time interval to induction or delivery, nor does it decrease the cesarean rate.
authors.affiliation: Department of Obstetrics and Gynecology, Orlando Regional Healthcare System, Arnold Palmer Hospital for Children and Women, Florida.
authors.forename: S J
authors.initials: SJ
authors.lastname: Carlan
authors.forename: P
authors.initials: P
authors.lastname: Danna
authors.forename: D
authors.initials: D
authors.lastname: Durkee
authors.forename: C
authors.initials: C
authors.lastname: Quinsey
authors.forename: B
authors.initials: B
authors.lastname: Lanaris
mesh_terms: D000282:Administration, Intravaginal; D000293:Adolescent; D002584:Cervix Uteri / Q000187:drug effects* / Q000502:physiology; D015232:Dinoprostone / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005782:Gels; D006801:Humans; D007751:Labor, Induced / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome; D013997:Time Factors; D016896:Treatment Outcome; D014590:Uterine Contraction / Q000187:drug effects*
chemical_list: D005782:Gels; D015232:Dinoprostone